LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is also pursuing the sale of its remaining pipeline assets.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for LIANY. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: LIANY is a Sell candidate.
LIANY stock price ended at $0.14 on 星期二, after rising 16.67%
On the latest trading day May 05, 2026, the stock price of LIANY rose by 16.67%, climbing from $0.13 to $0.14. Throughout the session, the stock experienced a volatility of 27.27%, with prices fluctuating between a daily low of $0.11 and a high of $0.14. Alongside this price increase, trading volume also rose by 24.1K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 843 shares were traded, amounting to a market value of approximately $15.1M.